RussianPatents.com

Method of treating endometritis in cows

Method of treating endometritis in cows
IPC classes for russian patent Method of treating endometritis in cows (RU 2475253):
Another patents in same IPC classes:
Agent antiactinomycilline for treating actinomycosis and necrobacillosis in farm animals Agent antiactinomycilline for treating actinomycosis and necrobacillosis in farm animals / 2475244
Invention relates to veterinary science. The agent contains, wt %: wildflower honey 3.0-5.0, pine turpentine 5.0-8.0, melted (cow) butter 12.0-15.0, anaesthesine 0.5-1.0, glycerol 0.5-1.5, ethanol 20.0-25.0, potassium iodide 2.0-2.5, salicylic acid 3.0-5.0, 9% vinegar 6.0-8.0, Novocaine (powder) 1.0-1.5, distilled water - the rest.
Method of treating acute and aggravated chronic laryngitis / 2474431
Invention refers to medicine and aims at treating acute and aggravated chronic laryngitis. What is involved is specific antibioticotherapy per os with additional examination of microflora starting from the 3rd-5th day of the therapy followed by instillations of specific, result-related bacteriophagues into the larynx in the amount of 0.5-1.0 ml in acute laryngitis for 7-10 days, and in aggravations for 10-14 days.
Universal vaccine for treating and preventing lyme disease applicable in human and veterinary science, and method for preparing it / 2472525
Invention refers to medicine, and concerns a universal vaccine for treating and preventing Lyme disease to be applied in veterinary science, based on a whole-cell bacterial vaccine or bacterial lysates or purified preparations, containing the three most pathogenic genospecies Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii, each of which simultaneously contains both immunogenic protective proteins of the outer membranes OspA and OspC.
Moxifloxacin aqueous formulation for parenteral introduction / 2472507
Present invention refers to chemical-pharmaceutical industry and presents a moxifloxacin aqueous formulation for parenteral introduction containing an active substance: moxifloxacin hydrochloride, water for injections and other ingredients used for parenteral introduction differing by the fact that said ingredients are presented by sodium ascorbate and sodium metabisulphite in the following proportions, g/l: moxifloxacin hydrochloride 15-25; sodium ascorbate 0.05-1; sodium metabisulphite 0.1-2; water for injections up to 1 l.
3-amino-6-(1-aminoethyl)tetrahydropyrane derivatives 3-amino-6-(1-aminoethyl)tetrahydropyrane derivatives / 2471795
Invention refers to new antibacterial compounds of formula I
Mutant antigens gas57 and gas57 antibodies Mutant antigens gas57 and gas57 antibodies / 2471497
Group of invention refers to medicine, particularly to producing a mutant antigen GAS57 containing an amino acid modification in two or more positions of amino acids specified in a group consisting of consisting of amino acids D151, H279 and S617 wherein said positions of amino acids are numbered according to SEQ ID N0:1 which is not able to split IL-8 and analogous substrates with keeping an ability to provide protection of the infections caused by S. pyogenes. The group of inventions also comprises a nucleic acid molecule coding a purified mutant antigen GAS57, a method for producing a mutant antigen, a composition and a method for producing it, a method for treating or preventing an infectious disease caused by S. pyogenes. Said mutants may be used inter alia in vaccine compositions.
Method for preparing composition for injections containing sodium cevtriaxone and sodium tazobactam / 2471484
Method for preparing a composition for injections containing sodium cevtriaxone and sodium tazobactam involves the following stages: (a) suspension of raw materials, i.e. sodium cevtriaxone, sodium tazobactam, sterilised water for injections, mixed solution of ethyl acetate and isopropyl alcohol, and anhydrous ethanol in mass relation making 3-5:1:2:5:9, with volume relation of ethyl acetate to isopropyl alcohol making 1:2-4; (b) dissolution of sodium cevtriaxone and sodium tazobactam in sterilised water for injections with added activated hydrocarbon and filtration; (c) addition of the mixed solution of ethyl acetate and isopropyl alcohol to the filtrate and agitation of the mixture; addition of a seed crystal of sodium cevtriaxone to the solution for crystallisation initiation; and finally washing of the crystals in anhydrous ethanol and crystal drying; and (d) lyophilisation to form the composition for injections containing sodium cevtriaxone and sodium tazobactam.
Complex composition of chitosan succinate and chlorhexidine possessing antibacterial and wound healing effect Complex composition of chitosan succinate and chlorhexidine possessing antibacterial and wound healing effect / 2471477
Invention refers to medicine. What is described is a complex of chitosan and dioxydine with chlorhexidine at mass ratio of chitosan succinate with dioxidine 4.25-6:1 and chlorhexidine 60-85.0:1 respectively.
Method for integrated treatment of maxillofacial abscesses and phlegmons in children by ointment with furacilin, lidocaine and dibunol / 2470629
Offered invention refers to medicine, namely dentistry, and may be used for treating children suffering maxillofacial abscesses and phlegmons. That is ensured by opening of a suppurative focus, wound bathing and drainage. With underlying conventional antibacterial therapy, an ointment containing furacilin, lidocaine and dibunol as active agents and a styrene maleic anhydride copolymer, Lutrol F-127 and purified water in certain proportions as an ointment base is introduced in the suppurative cavity. Furacilin - 0.2, Lidocaine - 5.0, Dibunol - 5.0, Styrene maleic anhydride copolymer - 2.0, Lutrol F-127 2.0 and Purified water to 100.0.
Composition for treatment or prevention of gastrointestinal infection / 2469735
Composition for treatment and/or prevention of infection with gastrointestinal pathogens and/or disease of mammals, associated with infection by said pathogens, contains lipid, protein and hydrocarbon part, where lipid part provides from 5 to 50% of total number of calories, protein part provides from 5 to 50% of total number of calories and carbohydrate part provided from 15 to 90% of total number of calories. Protein part contains: (i) pea protein hydrolysate and (ii) at least one source of nitrogen, selected from the group, consisting of milk proteins, milk protein hydrolysate, egg protein and egg protein hydrolysate.
Agent for external therapy of chronic recurrent inflammatory dermatopathies / 2475249
What is presented is the use of xenon in the form of an agent for external therapy of chronic recurrent inflammatory dermatopathies prepared by extra pure grade xenon saturation of a fatty base.
Heteroaryl compounds, their compositions and use thereof as protein kinase inhibitors Heteroaryl compounds, their compositions and use thereof as protein kinase inhibitors / 2474582
Invention refers to new heteroaryl compounds of general formula (I) and their pharmaceutically acceptable salts possessing the properties of protein kinase inhibitor, such as mTOR, IKK-2, Tyk2, Syk-kinase. In formula (I) R1 represents substituted or unsubstituted C1-8alkyl, substituted or unsubstituted aryl, specified in phenyl, substituted or unsubstituted 5-6-member heteroaryl with 1-3 nitrogen atoms in a cycle specified in pyridine, pyrazole, indole, indazole, triazole, benzimidazole, 2-(1H-imidazo-[4,5-b]pyridine, substituted or unsubstituted 5-7- member cycloalkyl or substituted or unsubstituted heterocycloalkyl specified in pyrrolidinyl; -X-A-B-Y- taken together form -N(R2)CH2C(O)NH-, -N(R2)C(O)CH2NH-, -N(R2)C(O)NH-, -N(R2)C=N- or -C(R2)=CHNH-; L represents a direct bond, NH or O; R2 represents substituted or unsubstituted C1-8alkyl, substituted or unsubstituted aryl specified in phenyl, tetrahydronaphthalene, unsubstituted 5-7- member mono- or 8- member bicycloalkyl; and R3 and R4 independently represent H or C1-8alkyl. The substitutes in the substituted groups are specified in one or more halogen, C1-8alkyl, hydroxyl, amino, nitro, thiol, C1-4alkyl thioether, cyano, carboxyl, C1-4alkyl ester, halogen alkyl, C6cycloalkyl or heteroaryl specified in pyridyl, triazole, O-lower alkyl, aryl specified in phenyl, phenyl-lower alkyl, CO2CH3, CONH2, OCHF2, CF3 or OCF3 groups wherein CONH2 group may be substituted by cyclohexyl.
Novel tetrahydroisoquinoline derivative, pharmaceutical composition based thereon, use thereof and method of treating and/or preventing disease Novel tetrahydroisoquinoline derivative, pharmaceutical composition based thereon, use thereof and method of treating and/or preventing disease / 2474575
Invention relates to novel tetrahydroisoquinoline derivatives of general formula (I) or pharmacologically acceptable salts thereof, where R1 is a phenyl aminocarbonyl group which can be substituted with 1-3 groups independently selected from a substituting group A, a heteroaryl aminocarbonyl group, where the heteroaryl is pyridine, pyrazine, thiazole, pyrazole or isoxazole, which can be substituted with 1 group selected from a substituting group A, benzoxazol-2-yl group, which can be substituted with 1 group selected from a substituting group A, benzothiazol-2-yl group, (C1-C6 alkyl which can be monosubstituted with a C3-C6 cycloalkyl group), aminocarbonyl group, (C3-C6 cycloalkyl)aminocarbonyl group or adamantyl aminocarbonyl group; R2 independently represents a C1-C6 alkyl group; R3 is a heterocyclic group, where the heterocycle is oxazole, oxadiazole, pyrazole, isoxazole or tetrazole, which can be substituted with 1 group selected from a substituting group A, a group of formula -C(=O)-O-R4, or a group of formula -C(=O)-N(R5)R6; R4 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1-2 groups independently selected from a substituting group B; R5 is a hydrogen atom, a C1-C6 alkyl group which can be substituted with 1 group selected from a substituting group B, a C3-C6 cycloalkyl group which is monosubstituted with a carboxyl group, or a heterocyclic group, where the heterocycle is tetrazole, which can be substituted with 1 group selected from a substituting group A; R6 is a hydrogen atom or a C1-C6 alkyl group; in those cases when both R5 and R6 represent a C1-C6 alkyl group, which can be substituted with 1 group selected from a substituting group B, their carbon atoms can be bonded to each other to form a 5-member saturated ring; X is an oxygen atom, a methylene group, a group of formula -NH-, a methylene group which is monosubstituted with a C1-C6 alkyl group, or a group of formula -N(R7)-; R7 is a C1-C6 alkyl group; L is a single bond, a methylene group, a 1,1-dimethylmethylene group, an ethylene group, a group of formula - CH=, or a methylene group which is monosubstituted with a C1-C6 alkyl group; … denotes a single bond or a double bond (however, … denotes a single bond when L is a group of formula -CH=); m equals 1 or 2; n equals 0 or 1; substituting group A is a group of substitutes selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, a C1-C6 alkylthio group, a carboxyl group, a di-(C1-C6 alkyl)amino group, a cyano group, a hydroxy group, a C1-C6 alkylthionyl group and an oxo group; and substituting group B is a group of substitutes selected from a carboxyl group and a hydroxy group. The invention also relates to a pharmaceutical composition based on the compound of formula (I), use of the compound of formula (I) and a method of treating and/or preventing a disease.
Adhesive plaster Adhesive plaster / 2474418
Invention refers to medicine. What is described is an adhesive plaster containing an elastic carrier and an adhesive layer applied on at least one side of the carrier wherein the elastic carrier contains a woven material knitted by stocking stitch on both sides, containing two or more lines of wavy multifilament PET yarns; the adhesive layer contains 25 to 50 wt % of a liquid organic ingredient and 25 to 50 wt % of a thermoplastic elastomer in relation to total weight of the layer, and contains 10 wt % or more of methyl salicylate as a liquid organic ingredient in relation to total weight of the layer, and a dynamic modulus of elasticity (G') of the adhesive layer makes 30000 to 75000 Pa at 10 rad/s and 37°C.
C3b antibodies and methods for prevention and treatment of complement-related disorders C3b antibodies and methods for prevention and treatment of complement-related disorders / 2473563
Present invention refers to immunology and biotechnology. There are presented versions of C3b antibodies each of which is characterised by the presence of six CDR and does not bind C3. What is described is a pharmaceutical composition on the basis of the antibody and a set used for prevention and treatment of a complement-related disorder.
Tapentadol for treatment caused by osteoarthrosis Tapentadol for treatment caused by osteoarthrosis / 2473337
Claimed is application of tapentadol for manufacturing medication for treatment of pain caused by osteoarthrosis, in which at the beginning of treatment amount of taken in tapentadol is gradually increased in order to avoid side effects (titration from 25 mg two times per day to 200 mg two times per day).
((bicycloheteroaryl)imidazolyl)methylheteroaryl compounds as agonists of adrenergic receptors ((bicycloheteroaryl)imidazolyl)methylheteroaryl compounds as agonists of adrenergic receptors / 2472788
Invention relates to novel imidazole derivatives of formula where A is pyridinyl; and B is a condensed ring system consisting of: a. a phenyl ring bonded to a molecular residue, b. a second heterocyclic 5- or 6-member ring which is condensed with the phenyl ring, and has one nitrogen or oxygen atom, and to tautomeric forms thereof.
13-isopropyl-4,10-dimethyldodecahydro-13,16-epoxyoxireno[2,3]naphtho[2,1-d][1,2]dioxycin-4-carboxylic acid agent, exhibiting anti-inflammatory and antiulcer activity 13-isopropyl-4,10-dimethyldodecahydro-13,16-epoxyoxireno[2,3]naphtho[2,1-d][1,2]dioxycin-4-carboxylic acid agent, exhibiting anti-inflammatory and antiulcer activity / 2472787
Invention relates to the chemical and pharmaceutical industry and specifically to an agent which is 13-isopropyl-4,10-dimethyldodecahydro-13,16-epoxyoxireno[2,3]naphtho[2,1-d][1,2]dioxycin-4-carboxylic acid of formula:
Bicyclosulphonyl acid (bcsa) and use thereof as therapeutic agent Bicyclosulphonyl acid (bcsa) and use thereof as therapeutic agent / 2472784
Invention relates to bicyclosulphonyl acid (BCSA) compounds of formula: where: where each of -Rpw, -Rpx, -RPY, and -RPZ independently denotes H or -RRS1; each -RRS1 independently denotes -F, -Cl, -Br, -I, -RA1, -CF3, -OH, -OCF3 or -ORA1; where each RA1 independently denotes C1-4alkyl, phenyl or benzyl; and additionally, two neighbouring -RRS1 groups can together form -OCH2O-, -OCH2CH2O- or -OCH2CH2CH2O-; -RAK independently denotes a covalent bond, -(CH2)- or -(CH2)2-; -RN independently denotes -RNNN, or -LN-RNNN; the rest of the values of the radicals are given in claim 1, which act as inhibitors of inhibitors of tumor necrosis factor-α converting enzyme (TACE).
Amine derivatives and use thereof in beta-2-adrenoreceptor mediated diseases Amine derivatives and use thereof in beta-2-adrenoreceptor mediated diseases / 2472783
Invention relates to a compound of formula (I) , where Ar denotes each of R2, R3, R4, R5, R4' and R5' denote hydrogen; A denotes C(O); D denotes oxygen or NR8; E denotes CR63R64CR65R66; R63 and R64 denote hydrogen; R65 and R66 independently denote hydrogen or C1-4alkyl; k equals 0; m equals 1; R6 denotes a group -(X)p-Y-(Z)q-R10, or R6 denotes α- or β-branched C3-6alkyl (optionally substituted with C6cycloalkyl); X and Z independently denotes a C1-4alkylene group; p and q are independently equal to 0 or 1; Y denotes a bond; R8 denotes hydrogen; R10 denotes hydrogen or a saturated 5-7-member ring system; R7 denotes a 6-member aromatic ring, optionally substituted with a halogen, carboxyl, C1-6alkyl, C1-2alkoxy or a 5-member heteroaromatic ring (which is optionally substituted with C1-6alkyl); or a pharmaceutically acceptable salt thereof. Compounds of formula (I) or a pharmaceutically acceptable salt thereof are used to produce a medicinal agent for treating respiratory distress syndrome (ARDS), pulmonary emphysema, bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), asthma or rhinitis.
Method of treating acute orchiepididymitis and their complications / 2475241
Invention refers to medicine, namely urology, and may be used for treating acute orchiepididymitis and their complications. With underlying antibacterial therapy, a local therapy is applied. That is ensured by localising a spermatic cord on the border between a scrotum and an external inguinal ring, fixing it with fingers to perform local anaesthesia with 0.5% Novocaine 1-2 ml to create an infiltration round. Thereafter, a needle is pushed forward in a proximal direction, and recombinant interleukin-2 500000 IU 2 ml with 0.5% Novocaine 40 ml is introduced.

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. There are involved the intrauterine infusions of the ozonised emulsion 100.0 ml consisting of equal portions of cod liver oil and linseed infusion every 48 hours until clinical recovery is observed.

EFFECT: method is simple and high-effective in treating endometritis in cows.

9 tbl, 1 ex

 

The invention relates to veterinary medicine, namely to the veterinary obstetrics, and can be used for the treatment of endometritis in cows.

Known methods, techniques, and patterns [1, 2] treatment of endometritis: causal, pathogenesis, symptoms, physiotherapy, mud, denaturate and others. The basis of a comprehensive treatment of animals with inflammatory processes in the reproductive organs are antimicrobials. As antimicrobial agents used antibiotics, sulfonamides, nitrofurans and other antiseptic.

The disadvantages of their application include high cost, low efficiency because of the narrow focus with respect to microorganisms, negative impact on the performance of nonspecific resistance of the organism and on the morphofunctional state of the mucous membrane of the uterus, and on the background of immunodeficiency of the host they can cause relapse and recurrence of the carrier state, occurrence in nature, highly resistant strains of microorganisms and inflammation fungal etiology. It is established that in any way the introduction of antibiotics, sulfonamides and nitrofurans can accumulate in the organism of animals and a long period of time stored in animal products. Antibiotics and sulfonamides, opada in the body of the animal and human can cause an allergic reaction, anaphylaxis, a change in the quantitative and qualitative composition of the bacterial microflora and other undesirable phenomena.

The known method [2] etiotropic therapy of cows suffering from endometritis, which is based on intrauterine injection of the emulsion godisgoodalltime at a dose of 50-100 ml.

The disadvantage of this method of treatment is, first of all, the deficit on the market, high cost, lack of therapeutic efficacy, the need for rejection of milk during treatment and for 2 days after the disappearance of clinical signs of disease.

The essence of the proposed method lies in the fact that for the treatment of endometritis in cows offered General similar to the prototype sign - etiotropic therapy. In relation to the prototype hallmark is the use of ozonated emulsion. Preparing an emulsion of equal parts of fish oil and extract of flax seed (obtained by infusion within 30 minutes of flax seeds in boiled water at a ratio of 1:30). Ozonation of the emulsion is carried out with the use of ozone in ozone concentration at the outlet of the device 20 mg/l for five hours, which is later used for the treatment of endometritis in cows by intrauterine injections.

Held a number of Toxicological studies using the m ozonated emulsion. To determine the acute toxicity of ozonated emulsion was diluted with sterile saline solution from step 2. Each dilution homogenized until a homogeneous emulsion was injected intraperitoneally white mice.

The maximum of the injected doses were 0.5 ml, which exceeded more than 20 therapeutic doses. The amount of a therapeutic dose was calculated based on the planned therapeutic doses for cows (50 ml), taking into account the ratios of mass and surface area of the animal body.

After the introduction of the tool after the animals were observed for 7 days, recording their death, as well as other manifestations of intoxication (behavioral change, temperature reactions, weight loss).

White mice of the control group were injected intraperitoneally with saline in a volume of 0.5 ml.

After 24 hours, and 7 days from the moment of introduction of the emulsion and the saline solution of sodium chloride of the animals from each group were euthanized ether anesthesia for evaluation of pathological and histological picture. With the same purpose were subjected to autopsy all fallen in the course of the trial animals.

During the observation period of individual animals comprising the experimental group to which the drug was administered in the maximum doses were recorded cases of refusal of food, reduction of motor activity, shiroshi is the use of wool. The results of the experiment are summarized in table 1.

Table 1
Manifestations of acute toxic action of ozonized emulsion
Qty entered emulsion, therapeutic doses Number of animals in the group Number of animals with signs of toxicity The number of dead animals
weight the temperature change the behavioural change
12 6 0 0 3 2
6 6 0 0 1 0
3 6 0 0 0 0
1,5 6 0 0 0 0
0,75 6 0 0 0 0

The value of LD50intraperitoneal injection was 0,562 ml, which exceeds the estimated therapeutic dose more than 20 times.

At the opening of the fallen during the experience of the animals observed phenomenon of redistribution of blood from her deposition in parenchymal organs of varying severity. The mucous membranes were hypermonogenic, with numerous punctate hemorrhages. There was no visible bleeding in the brain and internal organs. In cavities of a small amount of exudate mixed with blood elements.

The dissection of animals experimental and control groups, sleeping in the control period, did not reveal the pathology of internal organs.

For histological studies in animals were selected pieces of brain, kidney, adrenal, heart, liver and lung was fixed with 10%formaldehyde solution and embedded in paraffin. Sections were stained with hematoxylin-eosin. In the study of sectional material from dead animals registered numerous small hemorrhages in internal organs, disorganization CT is homicidal, dystrophic changes in cortical and cerebral layer of the adrenal glands. Signs of inflammation were not found.

To determine the chronic toxicity of ozonated emulsion was injected intraperitoneally two groups of mice in amounts of, respectively, one (0,02 ml) and two (0,04 ml) therapeutic doses taken in a volume of 0.5 ml of the Drug was injected five times with an interval between injections one day. Animals of the control group during the same period in the amount of 0.5 ml was injected intraperitoneally with saline.

Monitoring of laboratory animals was carried out during the entire period of injection, and within 7 days from the date of the last injection, by registering with possible manifestations of intoxication. After 24 hours, and 7 days from the date of the last data entry solutions of animals are put to sleep with chloroform to assess pathological picture.

During the observation period the animals ' death, as well as other pathological manifestations has not been registered. At necropsy, animals were observed uniformity of macroscopic picture: cavity without exudate, serous covers the regular color, internal organs without features, regular size, color and consistency. Signs of malnutrition, inflammation and hemodynamic disorders are not identified. Histological examination sectional mother who La also did not reveal pathological changes of internal organs.

For the evaluation of local action ozonated emulsion was administered to a group of white mice intramuscularly five times, with an interval of one day. The volume of emulsion for a single injection were 0.02 ml (one therapeutic dose). The control group of animals to the same extent and in the same time introduced a physiological solution of sodium chloride.

Observation of the animals was carried out during the whole period of the experiment, and within 7 days from the date of the last injection. On the availability of local damaging actions judged on the basis of data daily inspection of the place of introduction, and also by results of histological examination of the muscle tissue of animals euthanized with chloroform for 24 hours after the last injection and at the end of the observation period.

During the observation of signs of local inflammation and irritation of the drug was not detected.

The definition of immediate type hypersensitivity was performed by the method of playback of anaphylaxis in Guinea pigs. For this animal was previously senzibilizirani by a threefold introduction of ozonated emulsion with an interval between injections one day. First sensitizing injections were performed subcutaneously, two subsequent injections. The amount of emulsion to a single injection was 0.12 ml (estimated treatment e is for Guinea pigs). Two weeks after the final sensitizing injections the animals were injected intraperitoneally allowing the dose of the emulsion (0.25 ml), and then watched them for 30 minutes. The severity of the shock was evaluated according to the following scale:

A - theresiana wool, scratching paws muzzle.

B - periodic sneezing, lowering the temperature;

In - spastic cough syndrome, falling on his side;

Mr. sharp respiratory failure, convulsions, and death within 5...7 minutes;

E - there has been no reaction.

The index of the syndrome in the group was calculated by the formula Vaigla

Animals of the group of negative control instead of the pre-sensitizing injections according to the same scheme was injected with saline.

As a positive control animals were used, prepared for the shock sensitization of normal horse serum, introduced subcutaneously twice, in an amount of 0.1 ml per two weeks before the resolution intracardiac injection of this drug in a quantity of 0.2 ml of the results of the experiment are summarized in table 2.

Table 2
Manifestations of anaphylaxis in Guinea pigs
№ p/p The name of the group The number of animals in group The number of animals with signs of anaphylaxis The index of the syndrome in the group
And B In G D
1 Experienced 15 0 0 0 0 15 0
2 The positive control 10 1 4 3 2 0 2,6
3 Negative control 10 0 0 0 0 10 0

Presented in table 2 data show that ozonated emulsion does not have anafilakticheskogo actions on Guinea pigs.

The delayed-type hypersensitivity characterized by change in mass of limbs animals.

This white mice were senzibilizirani intraperitoneally twice, with an interval of one day one therapeutic dose of ozonated emulsion (0,02 ml). Later, 5 days after the last sensitizing injections in the tip of one of the rear paws were administered 0.05 ml of ozonated emulsion, the other the same amount of saline. A day later, animals were euthanized with chloroform, the hind legs were amputated at the level of the heel joint and held their weigh-in. According to the difference of the mass of the legs were assessing the inflammatory reaction (edema). The swelling index was calculated by the formula

The mass of experienced paws;

VK - weight control paws.

As a control in this experiment, animals were used that instead of the pre-sensitizing injections in the same period and in the same volume was injected with saline. The results of the experiment are presented in table 3.

Table 3
Symptoms of delayed-type hypersensitivity in white mice
Preparation for sensitizing injections Average weight experienced paws mg The average weight of the control paw mg Index of edema in the group %
Ozonated emulsion 145,4 142,7 1,89
Saline of 148.6 145,8 1,92

As seen from the digital data in table 3, the index of edema in both groups are almost identical, which suggests that ozonated emulsion does not cause hypersensitivity reactions of the delayed type.

Thus, in recommended doses ozonated emulsion is not toxic to animals, causing no symptoms of hypersensitivity reactions immediate and delayed type.

Conducted a study of antimicrobial activity of ozonized emulsion on various concentratie microorganisms (Staphylococcus aureus and Escherichia coli). Used 3 rows of sterile test tubes of 10 pieces, where one row served as a control, and two were experienced. In each tube was made with 4.5 ml of physiological solution. Then in the first test tube experienced a number of standard turbidity received the initial concentration of the investigated microorgani the MOU in 10 9. Then, after thorough mixing transferred to the new measuring pipette 0.5 ml from one test tube to another, from the last test tubes 0.5 ml was poured. This has received a number of serial dilutions from 109up to 101. In the 1st experimental series was added 0.5 ml of ozonated emulsion, in the 2nd experimental Newtonian emulsion, and in the control and 0.5 ml of physiological solution. The resulting mixture was left for 30 minutes at room temperature with constant shaking. After a specified time 0.1 ml of the contents of the tubes were sown on an appropriate dense nutrient medium and incubated in an incubator at 37°C for 72 hours. Every 24 hours by direct counting of colonies grown on solid nutrient medium from the experimental and control series, conducted an assessment of antimicrobial activity. These experiments are displayed in tables 4,5.

Table 4
Antimicrobial activity of ozonized emulsion against E. coli
Index Time 109 108 107 106 105 104 103 102
Phys. solution 24 hours SPLR SPLR SPLR BKMC BKMC 151 19 -
48 h SPLR SPLR SPLR BKMC BKMC 151 19 -
72 h SPLR SPLR SPLR BKMC BKMC 151 19 3
Not ozonated emulsion 24 hours SPLR SPLR SPLR BKMC 1012 132 16 -
48 h SPLR SPLR SPLR BKMC 1012 132 16 -
72 h SPLR SPLR SPLR BKMC 1012 132 16 -
Ozonated emulsion 24 hours GROWTH NO
48 h
72 h

Table 5
Antimicrobial activity of ozonized emulsion against St. aureus
Index Time 109 108 107 106 105 104 103 102
Phys. solution 24 hours SPLR SPLR SPLR SPLR BKMC 764 68 1
48 h SPLR SPLR SPLR SPLR BKMC 776 71 3
72 h SPLR SPLR SPLR SPLR BKMC 776 71 3
Not ozonated emulsion 24 hours SPLR SPLR SPLR BKMC 964 284 46 -
48 h SPLR SPLR SPLR BKMC 964 284 46 -
72 h SPLR SPLR SPLR BKMC 964 284 46 -
Ozonated emulsion 24 hours GROWTH NO
48 h
72 h

From analysis of digital material tables 4 and 5 we can conclude that ozonated emulsion with this mode of bubbling ozone-oxygen mixture has a pronounced anti-microbial properties in relation to the collection of strains as E. coli, and St. aureus. The distinguishing feature is the complete absence of growth of colonies in the experimental series compared to control.

Examined therapeutic efficacy of intrauterine injection of ozonated emulsion with postpartum acute purulent-naturalmommie in cows after normal calving. The results of the experiment are presented in table 6.

Table 6
Comparative therapeutic efficacy of ozonated emulsion and 10%suspension, furazolidone fish oil for acute postpartum endometritis, developed after normal calving in cows (n=21)
Index Multiplicity of Therapeutic efficacy, % The rate of fertilization Number of days from recovery before pregnancy
Ozonated emulsion 7,1±0,3 90,5 1,8±0,02 52,0±4,1
10%suspension furazolidone fish oil 9,7±0,8 80,9 2,1±0,01 78,5±9,2

From digital material table 6 shows that the application of ozonized emulsion intrauterine cows, patients acute postpartum endometritis, 9.6% was more effective in comparison with 10%suspension of furazolidone. In addition, the CRA is of the introduction of ozonated emulsion on average 2.6 times was less in comparison with analog. Application of ozonized emulsion with the purpose of treatment led to higher rates of reproduction of the experimental cows was lower than 0.3, the rate of fertilization and 26.5 days shorter period of infertility).

In animals treated with ozonized emulsion, conducted a study of blood serum (table 7).

Table 7
Dynamics of biochemical indices of blood in cows recover from acute endometritis, emerged after normal calving, on the background of their treatment with ozonized emulsion (n=8)
Index On the day of disease After recovery After 10 days of recovery
Total protein, g/l 68,7±equal to 4.97 68,1±2,92 66,8±4,79
Total immunoglobulins, g/l 13,2±2.26 and 18,8±0,93 17,3±1,83
CEC3, EDEP 12,2±1,25 11,4±1,26 13,3±1,68
The CEC is 4, EDEP 24,0±2,3 25,3±2,1 27,1±1,3
With4:C3 1,9±0,1 2,2±0,2 2,0±0,2
Albumin, % 44,3±3,2 37,6±2,9 44,5±3,2
α - globulins,% 10,6±2,0 13,3±1,9 9,7±1,1
β - globulins, % 16,7±2,5 20,1±2,1 21,5±2,3
γ - globulins, % 28,4±0,7 29,0±2,4 24,3±1,5

Materials table 7 show that the process of clinical recovery of the cows in the background of the application of ozonized emulsion was accompanied by activation of antitelomerase sequential synthesis of specific antibodies and the formation of circulating immune complexes to large size.

Conducted an experiment to examine the comparative efficacy of ozonated emulsion and drug Metrolex-M with acute postpartum endometritis, which is RA who was vivalda after surgical separation of placenta in cows (table 8).

Table 8
Comparative therapeutic efficacy of ozonated emulsion and Metrolex-M with acute postpartum endometritis, developed after surgical separation of placenta in cows (n=10)
Index Multiplicity of Therapeutic efficacy,% The rate of fertilization Number of days from recovery before pregnancy
Ozonated emulsion 8,5±0,6 80 2,0±0,03 62,7±4,1
Metrolex-M 10,7±1,1 60 2,2±0,05 75,0±3,2

From digital data in table 8 shows that the application of ozonized emulsion was 20% higher than using Metrolex) it Should also be noted that the ozonated emulsion causes a reduction in the duration of treatment and infertility animals, 0.2 reduces the rate of fertilization.

In cows treated with ozonized emulsion, the origin of which was ladowali serum (table 9).

Table 9
Dynamics of biochemical indices of blood in cows recover from acute endometritis arising after surgical separation of placenta, on the background of their treatment with ozonized emulsion (n=5)
Index On the day of disease After recovery After 10 days of recovery
Total protein, g/l 65,3±7,9 61,7±3,0 64,4±3,3
Total immunoglobulins, g/l 14,3±2,4 18,5±1,8 14,1±2,7
CEC3, Edo. 19,7±3,0 18,68±1,1 13,9±3,2
CEC4, Edo. 31,3±5,6 28,1±3,7 31,6±2,9
With4:C3 1,5±0,07 1,2±0,04 2,5±0,02
Album the us, % 49,0±2,8 39,0±5,1 42,4±3,5
α - globulins % 5,6±1,6 9,9±2,1 8,5±1,4
β - globulins % 11,6±1,6 21,2±1,8 20,7±2,9
γ - globulins % 33,8±2,1 29,9±3,7 28,4±1,5

Analysis of the results of the Hematology research (table) showed that in the course of the experiment, clinical recovery cows was accompanied by a decrease in the total protein due to active processes for the synthesis of specific antibodies involved in opsonization and elimination of antigens, as evidenced by high levels of circulating immune bodies of large size.

Therefore, the highest efficiency in the treatment of cows postpartum patients acute purulent-catarrhal endometritis, which occurs in cows after normal and abnormal labor, has intrauterine injection of ozonized emulsion.

Literature

1. Gavrish VG Intravenous method of treatment of endometritis in cows / Vggis, Yearjoin // Noncontagious Bo is esni animals: Mater, the Intern. scient. Conf., ]. 70 anniversary of Zooengineering faculty. - Kazan, 2000. - P.3-4.

2. Grigorieva I.E. the Treatment and prevention of endometritis in cows. M: Rosagropromizdat, 1988. - S. the prototype.

3. Patent of the Russian Federation No. 2311790. IPC A23D 9/04 (2006.01). The method of obtaining the ozonated emulsion / Platonov, VA, Klabukov ER, Konoplev I.G., Tregubov D.A.: applicants and patentees: GOU VPO "Kirov state medical Academy" of the Ministry of health and FSEI HPE "Vyatka state agricultural Academy Publ. 10.12. 2007. Bull. No. 34.

A method of treatment of endometritis in cows, including intrauterine introduction antimicrobial agent, characterized in that as an antimicrobial agent in intrauterine infuziruut to 100.0 ml ozonated emulsion consisting of equal parts of fish oil and extract of flax seed, every 48 h until clinical recovery.

 

© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.